#evidencesynthesis — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #evidencesynthesis, aggregated by home.social.
-
The WHA teleradiology resolution turns remote imaging services into an evidence, governance, and implementation-readiness question for market access teams. https://www.mattheneus.com/editorial/who-teleradiology-resolution-evidence-plan-2026-05-22 #HTA #EvidenceSynthesis #RegulatoryAffairs
-
Trial retention is now an HTA evidence-governance issue: missing outcomes can weaken comparative estimates, utility inputs, and reimbursement models. https://www.mattheneus.com/editorial/trial-retention-outcome-data-completeness-hta-evidence-governance-playbook-2026-04-22 #HTA #NMA #MAIC #EvidenceSynthesis #RegulatoryAffairs
-
HTA evidence teams are hitting a fragmentation wall: ITC, MAIC, NMA, RWE, modelling, and reporting now need one traceable workflow, not stitched-together handoffs. https://www.mattheneus.com/editorial/abangelabs-hta-studio-itc-foundation-end-to-end-hta-evidence-platform-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis #HealthEconomics
-
Germany’s Long/Post-COVID Annex VI move shows how weak comparative evidence can still reshape reimbursable care pathways when unmet need is high. https://www.mattheneus.com/editorial/g-ba-long-post-covid-annex-vi-off-label-four-drugs-evidence-lineage-2026-04-02 #HTA #EvidenceSynthesis #HealthEconomics
-
G-BA says concizumab's added benefit is not proven in haemophilia A because comparator alignment still decides whether evidence lands or unravels. https://www.mattheneus.com/editorial/g-ba-concizumab-haemophilia-a-added-benefit-not-proven-comparator-mismatch-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis
-
NICE’s fezolinetant decision is a live case study in how reimbursement can clear despite uncertain indirect evidence beyond placebo. The real lesson is comparator-bridge discipline, not false certainty. https://www.mattheneus.com/editorial/nice-fezolinetant-menopause-final-guidance-indirect-comparison-uncertainty-2026-04-02 #HTA #NMA #MAIC #EvidenceSynthesis #RegulatoryAffairs
-
RWE fails when it is treated as a late appendix instead of submission architecture. Canada and EU HTA now reward early evidence planning and traceable decision logic. https://www.mattheneus.com/editorial/rwe-submission-architecture-canada-eu-hta-evidence-planning-playbook-2026-04-01 #HTA #RWE #RegulatoryAffairs #EvidenceSynthesis
-
AI can already speed up evidence screening and extraction, but the latest validation signal says HTA teams should keep human oversight on judgment-heavy risk-of-bias work. https://www.mattheneus.com/editorial/ai-evidence-synthesis-validation-coverage-gap-playbook-2026-04-01 #HTA #EvidenceSynthesis #Pharma
-
When two NMAs disagree, the ranking usually isn’t the truth—it’s the output of study selection, population splits, and consistency choices. This playbook shows how to stress-test the decision question before a league table enters a dossier. https://www.mattheneus.com/editorial/when-two-nmas-disagree-similarity-consistency-governance-playbook-2026-04-01 #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
-
AMNOG haemophilia dossiers get much harder when inhibitor and non-inhibitor populations are split—this playbook explains the evidence architecture teams need before review. https://www.mattheneus.com/editorial/amnog-haemophilia-split-population-evidence-architecture-inhibitor-stratification-playbook-2026-03-26 #HTA #EvidenceSynthesis #RegulatoryAffairs
-
G-BA finds no added benefit for ixekizumab in paediatric enthesitis-associated arthritis after comparator-relevance review.
-
HAS France NMA Acceptability Framework: A Cross-Agency Evidence Planning Playbook.
-
NICE's New EQ-5D-5L Value Set: What It Means for QALY Utility Measurement and Cost-Effectiveness Submissions.
-
What NICE TA1142 Reveals About Biomarker-Stratified Evidence Standards and Stopping-Rule Design for First-in-Class Biologics.
-
Bridging HAS and IQWiG Evidence Standards: A Cross-Border Network Meta-Analysis Planning Playbook.
-
MHRA's patient-information modernisation and device advice refresh set a new evidence-operations baseline.
-
EMA Management Board ePI roadmap turns product-information governance into an HTA evidence operations priority.
-
NMA outputs are now shaping HTA timelines before submission—not after. If your evidence plan starts late, your access strategy starts behind. https://www.mattheneus.com/editorial/hta-value-nma-projections-evidence #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
-
Governance gets stronger when patient and consumer voice is formalized early in HTA. https://www.mattheneus.com/editorial/hta-consumer-panel-governance-playbook-singapore-ace-2026-03-29 #HTA #NMA #MAIC #RegulatoryAffairs #EvidenceSynthesis
-
Retractions can silently invalidate NMA assumptions days before dossier lock—if your evidence ops aren’t retraction-aware, you’re flying blind. New seven-day governance playbook: https://www.mattheneus.com/editorial/nma-retraction-ingestion-governance-playbook-2026-03-29 #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
-
EMA weekly PIP and PSUSA cadence is now an evidence-maintenance signal, not admin noise. https://www.mattheneus.com/editorial/ema-pip-psusa-weekly-cadence-evidence-maintenance-playbook-2026-03-10 #HTA #MAIC #EvidenceSynthesis #RegulatoryAffairs
-
CEE HTA bodies like Poland's AOTMiT face a dual challenge: aligning domestic benefit-assessment methodology with EU JCA evidence standards for ITC & NMA while preserving reimbursement integrity. A practical playbook for market-access teams.
https://www.mattheneus.com/editorial/aotmit-poland-itc-nma-eu-jca-evidence-standards-cee-market-access-playbook-2026-03-27
#HTA #NMA #EvidenceSynthesis #RegulatoryAffairs -
Publication bias is systematically under-tested in NMA dossiers — a scoping review of 22 critical appraisal instruments confirms no standardised decision rules exist. Comparison-adjusted funnel plots should be mandatory in HTA submissions: https://www.mattheneus.com/editorial/fallback-canary-publication-bias-nma-comparison-adjusted-funnel-plot-playbook-2026-03-28 #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
-
When certainty grades diverge, first-order loops often reveal where NMA confidence can break.
https://www.mattheneus.com/editorial/grade-dominant-first-order-loop-nma-certainty-evidence-cinema-2026-03-27
#HTA #NMA #EvidenceSynthesis -
CADTH Reimbursement Reviews: ITC and NMA Evidence Standards for Canadian Market Access. https://www.mattheneus.com/editorial/cadth-reimbursement-review-itc-nma-evidence-standards-canada-market-access-playbook-2026-03-26 #HTA #NMA #MAIC #EvidenceSynthesis #Pharma
-
Non-Proportional Hazards in Network Meta-Analysis: A Five-Step Governance Protocol for Time-to-Event HTA Submissions. https://www.mattheneus.com/editorial/fallback-canary-non-proportional-hazards-nma-tte-governance-playbook-2026-03-25 #HTA #NMA #EvidenceSynthesis #Pharma
-
G-BA Approves LDCT Lung Cancer Screening for German Statutory Health Insurance from April 2026
https://www.mattheneus.com/editorial/g-ba-ldct-lung-cancer-screening-statutory-health-insurance-germany-2026-03-13
#HTA #NMA #RegulatoryAffairs #EvidenceSynthesis -
Here's a fun one for #EvidenceSynthesis / #SystematicReview crowd 📚
@ZijunLi and me are doing a meta-analysis where we compare two groups.
We use the "Cohen's d" family of effect size metrics for the meta-analysis (comparing baseline to follow-up, immediate and later)
Some studies (e.g. smoking interventions) only report a percentage in each arm (e.g. % of smokers).
How to best convert these percentages into smth Cohen's d-ish? 🤔
We appreciate any help / boosting!
-
Here's a fun one for #EvidenceSynthesis / #SystematicReview crowd 📚
@ZijunLi and me are doing a meta-analysis where we compare two groups.
We use the "Cohen's d" family of effect size metrics for the meta-analysis (comparing baseline to follow-up, immediate and later)
Some studies (e.g. smoking interventions) only report a percentage in each arm (e.g. % of smokers).
How to best convert these percentages into smth Cohen's d-ish? 🤔
We appreciate any help / boosting!
-
Here's a fun one for #EvidenceSynthesis / #SystematicReview crowd 📚
@ZijunLi and me are doing a meta-analysis where we compare two groups.
We use the "Cohen's d" family of effect size metrics for the meta-analysis (comparing baseline to follow-up, immediate and later)
Some studies (e.g. smoking interventions) only report a percentage in each arm (e.g. % of smokers).
How to best convert these percentages into smth Cohen's d-ish? 🤔
We appreciate any help / boosting!
-
Here's a fun one for #EvidenceSynthesis / #SystematicReview crowd 📚
@ZijunLi and me are doing a meta-analysis where we compare two groups.
We use the "Cohen's d" family of effect size metrics for the meta-analysis (comparing baseline to follow-up, immediate and later)
Some studies (e.g. smoking interventions) only report a percentage in each arm (e.g. % of smokers).
How to best convert these percentages into smth Cohen's d-ish? 🤔
We appreciate any help / boosting!
-
Here's a fun one for #EvidenceSynthesis / #SystematicReview crowd 📚
@ZijunLi and me are doing a meta-analysis where we compare two groups.
We use the "Cohen's d" family of effect size metrics for the meta-analysis (comparing baseline to follow-up, immediate and later)
Some studies (e.g. smoking interventions) only report a percentage in each arm (e.g. % of smokers).
How to best convert these percentages into smth Cohen's d-ish? 🤔
We appreciate any help / boosting!
-
Top-journal NMA quality gaps now demand transitivity-first governance in HTA evidence programs
-
Adaptive trial outputs are colliding with economic modelling timelines: an HTA evidence governance playbook https://www.mattheneus.com/editorial/adaptive-trial-to-economic-model-lineage-hta-evidence-governance-playbook-2026-03-23 #HTA #NMA #MAIC #HealthEconomics #EvidenceSynthesis
-
Cross-country HTA evidence transfer is now a credibility bottleneck: a new 2026 review finds inverse-odds weighting dominates practice while true transportability remains limited. What’s your governance plan for target-population assumptions? https://www.mattheneus.com/editorial/hta-transportability-iosw-cross-country-evidence-transfer-playbook-2026-03-23 #HTA #MAIC #NMA #EvidenceSynthesis #RWE
-
G-BA’s March closure wave and new NMA quality data point to a stricter comparator-governance era
-
IQWiG reports added benefit not proven for lisocabtagene maraleucel in relapsed or refractory mantle cell lymphoma. https://www.mattheneus.com/editorial/iqwig-lisocabtagene-maraleucel-mcl-added-benefit-not-proven-unanchored-maic-2026-03-16 #HTA #MAIC #EvidenceSynthesis #Pharma
-
NCPE’s perioperative pembrolizumab position shows the bottleneck: cost-effectiveness under uncertainty when indirect evidence informs decisions.
-
Cochrane pilots responsible AI tools — abstract screening, full-text review, and NMA — using the RAISE framework for evidence synthesis. A new governance baseline for systematic reviewers and HTA teams. https://www.mattheneus.com/editorial/cochrane-ai-synthesis-march2026 #HTA #NMA #EvidenceSynthesis #RegulatoryAffairs
-
Cross-domain NMA transitivity stress-testing: a March 2026 playbook for decision teams https://www.mattheneus.com/editorial/cross-domain-nma-transitivity-stress-testing-playbook-2026-03-16 #HTA #NMA #MAIC #RegulatoryAffairs #EvidenceSynthesis
-
Treatment-duration assumptions can change who wins in comparative evidence—so governance now matters as much as modeling. https://www.mattheneus.com/editorial/model-based-nma-treatment-duration-governance-playbook-2026-03-16 #HTA #NMA #EvidenceSynthesis #HealthEconomics
-
Depression HTA decisions can fail when outcome scales are misaligned across trials—this playbook shows how to keep ITC/NMA comparisons decision-grade. https://www.mattheneus.com/editorial/depression-outcome-measurement-heterogeneity-itc-nma-comparability-playbook-2026-03-15 #HTA #NMA #MAIC #EvidenceSynthesis #RWE
-
New editorial: NICE TA1121 recommends acoramidis and formalises a comparator-bridge evidence standard in transthyretin cardiomyopathy
https://www.mattheneus.com/editorial/nice-acoramidis-ta1121-recommendation-maic-comparator-bridge-2026-03-15
#HTA #MAIC #EvidenceSynthesis #Pharma -
New HTA brief: SMC accepts Alyftrek for restricted NHSScotland use, with evidence lineage anchored in active-comparator CFTR-modulator studies
-
SMC submission-route mix in March 2026 signals a four-lane evidence architecture for faster HTA readiness
-
Anchored comparator discipline is becoming the differentiator for HTA-ready indirect evidence this year. https://www.mattheneus.com/editorial/anchored-itc-common-comparator-governance-playbook-2026-03-14
#HTA #MAIC #NMA #EvidenceSynthesis #RegulatoryAffairs -
SMC acceptance in grade 2 glioma sharpens the evidence signal for earlier treatment sequencing discussions. https://www.mattheneus.com/editorial/smc-vorasidenib-voranigo-acceptance-grade2-glioma-phase3-lineage-2026-03-09 #HTA #NMA #MAIC #EvidenceSynthesis #RegulatoryAffairs
-
PRAC safety updates can ripple into access strategy faster than most teams expect. https://www.mattheneus.com/editorial/ema-ixchiq-prac-aseptic-meningitis-product-information-update-2026-03-12 #HTA #NMA #MAIC #EvidenceSynthesis #RegulatoryAffairs
-
AbangeLabs ITC Studio: From MAIC-Centric Workflow to a Three-Ecosystem ITC Architecture. https://www.mattheneus.com/editorial/abangelabs-itc-studio-three-ecosystem-upgrade-executive-overview-2026-03-13 #HTA #NMA #MAIC #EvidenceSynthesis #Pharma
-
AI reporting lineage controls are becoming the decisive factor for HTA-ready evidence synthesis. https://www.mattheneus.com/editorial/ai-reporting-lineage-controls-hta-evidence-readiness-playbook-2026-03-12 #HTA #NMA #MAIC #EvidenceSynthesis #Pharma